Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Srikripa Devarakonda has reaffirmed a Buy rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $60 to $86.
December 28, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Srikripa Devarakonda maintains a Buy rating on Cytokinetics and raises the price target from $60 to $86, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst suggests a strong conviction in the company's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100